The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia

British Journal of Clinical Pharmacology

Volumn 61, Issue 3, 2006, Pages 321-325

  Davies, Benjamin J ^a,b   Coller, Janet K ^b   James, Heather M ^c   Somogyi, Andrew A ^b   Horowitz, John D ^a   Sallustio, Benedetta C ^a,b  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

Author keywords

CYP2D6; Cytochrome P450; Metabolic ratio; Perhexiline; Polymorphism; Therapeutic drug monitoring

Indexed keywords

CYTOCHROME P450 2D6; DRUG METABOLITE; HYDROXYPERHEXILINE; PERHEXILINE; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; CIS ISOMER; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; GENOTYPE; HEART MUSCLE ISCHEMIA; HUMAN; METABOLIC CAPACITY; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; AGED, 80 AND OVER; ALLELES; CARDIOVASCULAR AGENTS; CYTOCHROME P-450 CYP2D6; GENE FREQUENCY; GENOTYPE; HUMANS; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PERHEXILINE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 33644882225     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02570.x     Document Type: Article

References (23)

1. Burns-Cox CJ Chandrasekhar KP Ikram H Peirce TH Pilcher J Quinlan CD Rees JR Clinical evaluation of perhexiline maleate in patients with angina pectoris BMJ 1971 4 586 8
2. Singlas E Goujet MA Simon P Pharmacokinetics of perhexiline maleate in anginal patients with and without peripheral neuropathy Eur J Clin Pharmacol 1978 14 195 201
3. Morgan MY Reshef R Shah RR Oates NS Smith RL Sherlock S Impaired oxidation of debrisoquine in patients with perhexiline liver injury Gut 1984 25 1057 64
4. Cooper RG Evans DAP Whibley EJ Polymorphic hydroxylation of perhexiline maleate in man J Med Genet 1984 21 27 33
5. Kennedy JA Unger SA Horowitz JD Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone Biochem Pharmacol 1996 52 273 80
6. Kennedy JA Kiosoglous AJ Murphy GA Pelle MA Horowitz JD Effect of perhexiline and oxfenicine on myocardial function and metabolism during low-flow ischemia/reperfusion in the isolated rat heart J Cardiovasc Pharmacol 2000 36 794 801
7. Cole PL Beamer AD McGowan N Cantillon CO Benfell K Kelly RA Hartley LH Smith TW Antman EM Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent Circulation 1990 81 1260 70
8. Stewart S Voss DW Northley DL Horowitz JD Relationship between plasma perhexiline concentration and symptomatic status during short-term perhexiline therapy Ther Drug Monit 1996 18 635 9
9. Willoughby SR Stewart S Chirkov YY Kennedy JA Holmes AS Horowitz JD Beneficial clinical effects of perhexiline in patients with stable angina pectoris and acute coronary syndromes are associated with potentiation of platelet responsiveness to nitric oxide Eur Heart J 2002 23 1946 54
10. Sallustio BC Westley IS Morris RG Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose Br J Clin Pharmacol 2002 54 107 14
11. Davies BJL Coller JK James HM Somogyi AA Horowitz JD Sallustio BC Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline Br J Clin Pharmacol 2004 57 456 63
12. Zanger UM Fischer J Raimundo S Stüven T Evert BO Schwab M Eichelbaum M Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6 Pharmacogenetics 2001 11 573 85
13. Barclay ML Sawyers SM Begg EJ Zhang M Roberts RL Kennedy MA Elliott JM Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status Pharmacogenetics 2003 13 627 32
14. Zanger UM Raimundo S Eichelbaum M Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry Naunyn Schmiedebergs Arch Pharmacol 2004 369 23 37
15. Løvlie R Daly AK Matre GE Molven A Steen VM Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism? Pharmacogenetics 2001 11 45 55
16. Raimundo S Fischer J Eichelbaum M Griese EU Schwab M Zanger UM Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6 Pharmacogenetics 2000 10 577 81
17. James HM Coller JK Gillis D Bahnisch J Sallustio BC Somogyi AA A new simple diagnostic assay for the identification of the major CYP2D6 genotypes by DNA sequencing analysis Int J Clin Pharmacol Ther 2004 42 719 23
18. Raimundo S Toscano C Klein K Fischer J Griese EU Eichelbaum M Schwab M Zanger UM A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P4502D6 in white people Clin Pharmacol Ther 2004 76 128 38
19. Marez D Sabbagh N Legrand M Lo-Guidice JM Boone P Broly F A novel CYP2D6 allele with an abolished splice recognition site associated with the poor metabolizer phenotype Pharmacogenetics 1995 5 305 11
20. Griese EU Zanger UM Brudermanns U Gaedigk A Mikus G Mörike K Stüven T Eichelbaum M Assessment of the predictive power of genotypes for the in vivo catalytic function of CYP2D6 in a German population Pharmacogenetics 1998 8 15 26
21. Lundqvist E Johansson I Ingelman-Sundberg M Genetic mechanisms for duplication and multiplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes Gene 1999 226 327 38
22. Chou WH Yan FX Robbins-Weilert DK Ryder TB Liu WW Perbost C Fairchild M de Leon J Koch WM Wedlund PJ Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships Clin Chem 2003 49 542 51
23. Sorensen LB Sorensen RN Miners JO Somogyi AA Grgurinovich N Birkett DJ Polymorphic hydroxylation of perhexiline in vitro Br J Clin Pharmacol 2003 55 635 8